Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). [PDF]
J Crohns Colitiseuropepmc +1 more source
Beyond Serum Zinc: Expanding the Understanding of Mucosal Zinc Homeostasis in Ulcerative Colitis. [PDF]
J Gastroenterol HepatolSiddique A, Najaf DE, Shah HM, Ullah T.
europepmc +1 more source
Severe Chronic Anemia and Tumor-Mimicking Colonic Lesions as an Atypical Presentation of Crohn's Colitis. [PDF]
ACG Case Rep JAl Masad AG +2 more
europepmc +1 more source
Auricular Vagus Nerve Stimulation in Inflammatory Bowel Disease: Mechanistic Insights and Biomarker-Based Evaluation of Therapeutic Response. [PDF]
Int J Mol SciÖztürk EZ, Alataş M.
europepmc +1 more source
Defining Disabling Disease in Moderate-to-Severe Ulcerative Colitis: Beyond Treatment Escalation. [PDF]
J Gastroenterol HepatolAbubakar M, Usman M.
europepmc +1 more source
Immunosuppressive-Therapy Management and Day-14 Molecular Remission in Ulcerative Colitis Complicated by Cytomegalovirus Colitis: An Exploratory Prospective Cohort Study. [PDF]
Medicina (Kaunas)Islamoglu Z +4 more
europepmc +1 more source
Clarifying Composite Outcomes and Baseline Prognostic Analysis in Ulcerative Colitis. [PDF]
J Gastroenterol HepatolLee CK.
europepmc +1 more source
Atopic Dermatitis and Risk of Inflammatory Bowel Disease in Children: A Systematic Review and Meta-Analysis. [PDF]
CureusLoiacono A +7 more
europepmc +1 more source
Blood heavy metal and trace element levels in newly diagnosed cases of inflammatory bowel disease. [PDF]
Pak J Med SciAkbas E, Akın MS, Ulfer G.
europepmc +1 more source
Methodological Considerations in Defining Disabling Disease Trajectories in Moderate-to-Severe Ulcerative Colitis. [PDF]
J Gastroenterol HepatolAhmed S.
europepmc +1 more source